Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TDF

EU flag

International regulators collaborate on generics

EMA leads three-year pilot project to increase pre-market data sharing

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

FDA approves Gilead drug in three blood cancers

Zydelig recommended for use in chronic lymphocytic leukaemia and two forms of lymphoma

- PMLiVE

US senators seeks answers on Sovaldi pricing

Gilead asked to justify pricing of hepatitis drug

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

- PMLiVE

UCB taps EU for €75m in R&D funding

Agrees innovative risk-sharing finance deal with European Investment Bank

- PMLiVE

Hepatitis C therapies: dawn of a new age

New treatments from the likes of Merck & Co, Janssen and Gilead offer significant treatment advances

- PMLiVE

Gilead’s RSV drug clears mid-stage trial

Late-stage data demonstrates GS-5806 is effective in treating the infection

European Commission launches mHealth consultation

May lead to policy action by 2015

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

WHO raises red flag on hepatitis C drug pricing

Warns about cost of Gilead’s Sovaldi and J&J’s Olysio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links